Market revenue in 2023 | USD 58.2 million |
Market revenue in 2030 | USD 88.9 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.66% in 2023. Horizon Databook has segmented the Brazil central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is one of the emerging markets and offers lucrative growth opportunities for the central lab market. The country is characterized by the presence of a large, drug naïve, urban population consisting of common as well as rare disease profiles.
It has over 40% of Latin America’s 16,000 healthcare establishments and over 40 university-led and 60 private hospitals that perform clinical research in the country. These factors are anticipated to strengthen the country’s clinical research abilities in the near future and drive market growth.
The country has one of the fastest-growing pharmaceutical markets globally and attracts international pharmaceutical companies and contract research organizations by offering an investment-friendly environment as well as a relatively low prevalence of counterfeit drug products and rising government investments.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil central lab market , including forecasts for subscribers. This country databook contains high-level insights into Brazil central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account